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AbsTrACT
Objective serrated polyps (sPs) are an important cause 
of postcolonoscopy colorectal cancers (Pccrcs), which 
is likely the result of suboptimal sP detection during 
colonoscopy. We assessed the long- term effect of a 
simple educational intervention focusing on optimising 
sP detection.
Design an educational intervention, consisting of two 
45 min training sessions (held 3 years apart) on serrated 
polyp detection, was given to endoscopists from 9 Dutch 
hospitals. hundred randomly selected and untrained 
endoscopists from other hospitals were selected as 
control group. Our primary outcome measure was the 
proximal sP detection rate (PsPDr) in trained versus 
untrained endoscopists who participated in our faecal 
immunochemical test (FiT)- based population screening 
programme.
results seventeen trained and 100 untrained 
endoscopists were included, who performed 11 305 and 
51 039 colonoscopies, respectively. at baseline, PsPDr 
was equal between the groups (9.3% vs 9.3%). after 
training, the PsPDr of trained endoscopists gradually 
increased to 15.6% in 2018. This was significantly 
higher than the PsPDr of untrained endoscopists, which 
remained stable around 10% (p=0.018). all below- 
average (ie, PsPDr ≤6%) endoscopists at baseline 
improved their PsPDr after training session 1, as did 
57% of endoscopists with average PsPDr (6%–12%) at 
baseline. The second training session further improved 
the PsPDr in 44% of endoscopists with average PsPDr 
after the first training.
Conclusion a simple educational intervention was 
associated with substantial long- term improvement of 
PsPDr in a prospective controlled trial within FiT- based 
population screening. Widespread implementation of 
such interventions might be an easy way to improve sP 
detection, which may ultimately result in fewer Pccrcs.
Trial registration number ncT03902899.
InTrODuCTIOn
Colorectal cancer (CRC) is a leading causes of 
cancer- related mortality worldwide,1 2 and arises 
from premalignant polyps.3 CRC incidence can be 
reduced dramatically by removal of these polyps.4 
Adenomatous polyps have long been considered 
the only precursor lesion for CRC, and therefore 
CRC prevention has traditionally focused on detec-
tion and removal of adenomas. However, recent 
evidence shows that up to one- third of CRCs arise 
through serrated polyps (SP).5–7 This has caused a 
paradigm shift in CRC prevention; endoscopists 
should nowadays also detect and resect these SPs.8 9
However, due to the relative recent discovery 
of their malignant potential, the clinical relevance 
and appearance of SPs might be less well- known 
among endoscopists. In addition, detection of 
SPs is more difficult due to their flat shape, pale 
colour and vague borders. Furthermore, mucus is 
often attached to the polyp, thereby hiding it from 
the endoscopist’s eye.9 10 Two studies reported 
proximal SP detection rate (PSPDR) ranging from 
1%–2% in low- detecting endoscopists up to 18% 
in high- detecting endoscopists,11 12 suggesting that 
low detectors frequently miss SPs.
significance of this study
What is already known on this subject?
 ► Serrated polyps are precursor lesions to 
colorectal cancer, but are detected suboptimally 
by endoscopists, which might lead to 
postcolonoscopy colorectal cancers.
What are the new findings?
 ► Implementation of a brief and relatively simple 
educational intervention in a population 
screening setting resulted in substantial and 
long- term improvement of the detection of 
serrated polyps.
How might it impact on clinical practice in the 
foreseeable future?
 ► Adoption of this brief educational intervention 
in training and accreditation programmes could 
be a simple method to improve quality and 
effectivity of colonoscopy.
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Poor detection therefore seems to be one of the main chal-
lenges in the current management of SPs. This is illustrated by the 
disproportionally high contribution of SPs to the development 
of postcolonoscopy CRC (PCCRC): both molecular character-
istics as well as the preferential right- sided location of PCCRCs 
suggest that PCCRCs disproportionally often arise from missed 
or incompletely resected SPs.13–16
Analogous to the risk reduction of PCCRCs at increased 
adenoma detection rate (ADR),17 18 it therefore seems possible 
that an increase in SP detection will result in a decline in 
PCCRCs. Educational interventions aiming to improve adenoma 
detection have resulted in an increased ADR,19–21 but not in 
increased SP detection rates.22 Hence, dedicated interventions 
specifically aiming to improve SP detection seem warranted. To 
our knowledge, the effect of such educational interventions has 
not been studied.
We performed a study to evaluate whether a simple and easily 
applicable educational intervention consisting of two 45 min 
training sessions (approximately 3 years apart) on optimising SP 
detection, could lead to a long- term increase in SP detection in a 
large prospective controlled trial nested within the Dutch faecal 
immunochemical test (FIT)- based CRC screening programme.
MeTHODs
study design
In this prospective trial, we assessed the effect of a simple 
educational intervention on the detection of SPs in the Dutch 
nationwide CRC screening programme. All residents of the 
Netherlands aged 55–75 years are invited 2- yearly to perform 
an FIT. All individuals with a positive test result are invited for 
follow- up by colonoscopy. Each year, all residents from the same 
birth year are invited, thereby assuring comparable invitees 
throughout the country.
All endoscopists from nine Dutch hospitals spread throughout 
the Netherlands, performing colonoscopies in FIT- positives 
in the Dutch national screening programme, were invited to 
receive our educational intervention and were thus allocated to 
the intervention arm. This intervention consisted of two 45 min 
training sessions; one in 2014 and another one 3 years later (for 
details see paragraph ‘ Educational Intervention’ below). The 
selection of these nine centres was pragmatic, and mainly based 
on scattered location throughout the Netherlands. Hundred 
randomly selected endoscopists employed in other hospitals 
throughout the Netherlands were selected as controls.
Our study fell beyond the Dutch legislation regarding Medical 
Research Involving Human Subjects Act since patients were not 
exposed to any intervention, and because their privacy was guar-
anteed by anonymisation of the database.23 24 Patients were not 
involved in the design and conduct of this study.
Inclusion criteria
Endoscopists were eligible for inclusion if they were accredited 
to perform colonoscopies within the Dutch FIT- based screening 
programme. This meant all included endoscopists were subjected 
to strict quality monitoring and auditing throughout the study 
duration, which have been described in detail previously.25 
Briefly, among several other quality criteria, each endoscopist 
had to perform ≥200 colonoscopies per year, ≥50 polypecto-
mies per year and achieve a caecum intubation rate of ≥95%, 
withdrawal time of ≥6 min in ≥90% of colonoscopies, adenoma 
detection rate of ≥30%, removal of ≥90% of detected polyps 
and retrieval for pathological examination of ≥90% of resected 
polyps in screening colonoscopies.25 All screening colonoscopies 
performed by the included endoscopists were analysed to calcu-
late our primary and secondary end points.
exclusion criteria
Endoscopists allocated to the intervention arm who did not 
attend both training sessions were excluded for primary analysis. 
We performed a sensitivity analysis in which endoscopists that 
attended only one training session were included in the inter-
vention group. Endoscopists who did not perform screening 
colonoscopies before the first training session were excluded, 
since no baseline detection rates of these endoscopists could be 
established.
educational intervention
The educational intervention we implemented consisted of 
two training sessions. All endoscopists in the intervention arm 
received these two training sessions; one in 2014 and a second 
session in 2017 (two hospitals received the latter in October 
and November 2016, respectively). Training sessions were given 
by one of three research fellows specialised in serrated polyps 
(JEGI, AGCB and YJvH).
Training session 1 and 2 were almost identical. Both consisted 
of an oral presentation of about 45 min. The training sessions 
primarily focused on making endoscopists aware of the impor-
tance of diagnosing, detecting and resecting SPs. Statistics about 
the contribution of SPs to sporadic and postcolonoscopy CRC 
were presented, and typical features of the different SP subtypes 
(hyperplastic polyps (HPs), sessile serrated lesions (SSLs) and 
traditional serrated adenomas (TSAs)) were highlighted. Optical 
diagnosis of colorectal polyps using the Workgroup serrAted 
polypS and Polyposis classification was discussed.26 The slides 
of these presentations are available in online supplementary 
material.
Data collection: Dutch CrC screening programme
Data from the national CRC screening programme were used 
for our analyses. All colonoscopies in FIT- positives are routinely 
registered in this centralised database, which is coordinated by 
the governmental National Institute for Public Health and the 
Environment (Rijksinstituut voor Volksgezondheid en Milieu 
(RIVM)). This database includes detailed information of every 
colonoscopy performed in the population screening programme 
in the Netherlands, such as the endoscopist performing the 
endoscopy, caecal intubation, withdrawal time, polyp detection 
and resection. Histological data were extracted from PALGA, 
the nationwide network and registry of histopathology and cyto-
pathology in The Netherlands.27
For the purpose of this study, we extracted from this database 
all colonoscopies that were performed between January 2014 
and September 2018 by the included endoscopists.
All identifying variables were removed by employees of the 
RIVM before the data were made available to us in order to 
comply with privacy legislation of the European General Data 
Protection Regulation Act.24 As such, no personal information 
about endoscopists (eg, age, gender, years of experience) could 
be included in the provided data.
Outcome parameters
The primary outcome measure was the difference in PSPDR in 
colonoscopies performed by trained versus untrained endosco-
pists based on all colonoscopies performed by trained endosco-
pists after they received their first training, and all colonoscopies 
performed by the untrained endoscopists in the control arm. 
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PSPDR was defined as the percentage of patients in whom at 
least one SP proximal to the descending colon was removed.12 
The difference was expressed as absolute percentage and as OR 
for the detection of a proximal SP by control group versus the 
intervention group.
Secondary outcome measures included the detection rates of 
subtypes of SPs (ie, HP, SSL, and TSA) and (advanced) adenomas.
Another secondary outcome measure was the effect of our 
intervention on individual endoscopists. For this purpose, base-
line detection rates were measured using all colonoscopies prior 
to the first training session in 2014. The endoscopists were 
divided into three groups based on their baseline PSPDR: below- 
average (PSPDR ≤6%), average (PSPDR 6%–12%) and above- 
average (PSPDR ≥12%). The cut- off PSPDR values for these 
three groups were chosen arbitrarily based on baseline PSPDR. 
Baseline detection rates were compared with those after the 
first and the second training, respectively, for each individual 
endoscopist. The effect was assessed by quantifying how many 
endoscopists improved, remained stable or declined in PSPDR 
over time, with the three baseline strata as benchmark (ie, below- 
average, average and above- average).
statistical analyses
Detection rates of trained and untrained endoscopists were 
compared using mixed- effects logistic regression analysis. 
Training was analysed as a fixed effect into the model. To adjust 
for the fact that our data were clustered on endoscopist- level and 
for the fact that colonoscopies were performed in different types 
of centres (ie, academic hospital, general hospital, private clinic), 
we added random intercepts in the model for the endoscopist 
and the type of centre.
Differences in colonoscopy and patient characteristics were 
assessed using Mann- Whitney U tests (non- parametric numer-
ical variables) and χ2 tests (discrete variables). All analyses 
were performed using Statistical Package for Social Sciences 
V.24 (IBM, Somers, New York, USA) and RStudio28 with lme4 
package,29 with the function of glmer. Figures were produced 
using GraphPad Prism (V.7.03, GraphPad Software, La Jolla, 
California, USA).
Since at the time of initiation of our study in 2014 too little 
evidence was available about baseline PSPDR in a FIT- based 
cohort, and because we were unable to make a reliable estima-
tion about the number of colonoscopies per endoscopist, it was 
difficult to reliably produce the required parameters for sample 
size calculations. Instead, we therefore aimed to include as many 
endoscopists as possible in the intervention arm by selecting a 
relatively large number of hospitals for our intervention. The 
large number of control endoscopists was chosen pragmatically.
resulTs
baseline characteristics
A total of 34 endoscopists from 9 centres were potentially eligible 
for inclusion in the intervention arm. Eleven were excluded due 
to absence during one of the training sessions, while six were 
excluded because they did not yet perform colonoscopies for the 
population screening programme at the start of the study and 
thus no baseline PSPDR could be measured. Thus, 17 endosco-
pists attended both training sessions and were included in the 
intervention arm. In addition, 100 randomly selected untrained 
endoscopists were included as controls (table 1). Three trained 
endoscopists (18%) were employed in an academic hospital, 10 
(59%) in a general hospital and 4 (23.5%) worked mainly in 
a private clinic. In the control group, 3 (3%) of the untrained 
endoscopists worked in an academic centre, while 91 (91%) and 
6 (6%) were employed by general and private clinics, respec-
tively (table 1).
Endoscopists in the intervention arm performed a total of 
928 baseline colonoscopies (ie, colonoscopies in 2014 prior 
to the first training session), while endoscopists in the control 
arm performed 6069 baseline colonoscopies (ie, colonoscopies 
in 2014; table 1). Age and gender distribution of patients were 
similar between the intervention and control arm, but median 
inspection time of colonoscopy was longer (16 vs 13 min, 
p<0.001) for colonoscopies performed by endoscopists in the 
intervention arm. Detection rates at baseline did not differ across 
all different polyp subtypes (table 2).
After these baseline colonoscopies, trained and untrained 
endoscopists performed 10 377 and 44 967 post- training colo-
noscopies, respectively (table 1). Age and gender distribution of 
patients were similar, but colonoscopies performed by trained 
endoscopists had a longer median withdrawal time (17 vs 
13 min, p<0.001).
Primary outcome measure: PsPDr before and after training
After receiving their first training, trained endoscopists showed 
an increase in PSPDR from 9.3% at baseline to 12.5%, 13.0%, 
15.1% and 15.6% in 2015, 2016, 2017 and 2018, respectively 
(table 3 and figure 1A). In contrast, no clear improvement was 
seen in untrained endoscopists (figure 1A). When stratified per 
year of follow- up, the difference between trained and untrained 
endoscopists was non- significant in 2015 (p=0.08) and 2016 
(p=0.14), but statistically significant in 2017 (p=0.003) and 
2018 (p=0.04). The average PSPDR of trained endoscopists was 
35% higher than the PSPDR of untrained endoscopists (13.8% 
vs 10.2%, p=0.018).
PSPDR was not associated with the type of centre in which 
endoscopists worked: compared with academic hospitals, SPs 
were as frequently detected in general hospitals (p=0.48) and in 
private hospitals (p=0.45).
When stratifying for SP subtypes, trained endoscopists were 
more likely to detect both SSLs (9.7% vs 7.7%, OR 1.30 (95% 
CI 1.02 to 1.66), p=0.034) as well as HPs (22% vs 18%, OR 
1.30 (95%CI 1.02 to 1.66), p=0.035, table 3).
Sensitivity analyses
Because of the over- representation of academic centres among 
the group of trained endoscopists, we compared the post- training 
PSPDR of trained versus untrained endoscopists after exclusion 
of all colonoscopies performed in academic centres. This yielded 
similar results to our primary analyses, with an average post- 
training PSPDR for trained endoscopists of 14.3% vs 10.0% for 
untrained endoscopists (p=0.004).
Furthermore, we performed sensitivity analyses in which 
we included the subgroup of endoscopists (n=11) that partici-
pated in only one of the training sessions (online supplementary 
table 1). Based on the 3464 colonoscopies that these endosco-
pists performed after baseline, they showed a slight increase in 
PSPDR compared with baseline (10.6% at baseline vs 12.8%), 
but this was not significantly different compared with untrained 
endoscopists (OR 1.37, 95% CI 0.91 to 2.06, p=0.13).
effect of first and second training session on trained 
endoscopists
Based on baseline detection rates, we arbitrarily defined cut- 
off values to stratify endoscopists into below- average PSPDR 
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Table 1 Characteristics of endoscopists and colonoscopies
Included endoscopists (n=117)
Overall (n=117) Intervention arm (n=17) Control arm (n=100)
Type of centre of endoscopist, n (%)
  Academic hospital 6 (5.1%) 3 (18%) 3 (3.0%)
  General hospital 101 (86%) 10 (59%) 91 (91%)
  Private clinic 10 (8.5%) 4 (23.5%) 6 (6.0%)
Pretraining colonoscopies* (n=6997)
Characteristics of scoped patients
Overall (n=6997) Intervention arm (n=928) Control arm (n=6069) P value
Age, mean (SD) 71 (SD 5.1) 72 (SD 4.7) 71 (SD 5.1) <0.001
Male gender, n (%) 4119 (59%) 563 (61%) 3556 (59%) 0.24
Type of centre, n (%) <0.001
  Academic hospital 940 (13%) 226 (24%) 714 (12%)
  General hospital 5357 (77%) 574 (62%) 4783 (79%)
  Private clinic 700 (10%) 128 (14%) 572 (9.4%)
Quality parameters, n (%)
  Caecal intubation, n (%) 6642 (95%) 882 (95%) 5760 (95%) 1
  Inspection time, median (IQR) 14 (9–21) 16 (10–26) 13 (9–20) <0.001
  Inspection time ≥6 min 6541 (94%) 912 (98%) 5629 (93%) <0.001
  BBPS ≥2 in all segments 6727 (96%) 896 (96%) 5831 (96%) 0.94
Post- training colonoscopies* (n=55 344)
Characteristics of scoped patients
Overall (n=55 344) Intervention arm (n=10 377) Control arm (n=44 967) P value
Age, mean (SD) 66 (SD 5.3) 66 (SD 5.1) 66 (SD 5.4) 0.005
Male gender, n (%) 32 587 (59%) 6053 (58%) 26 534 (59%) 0.21
Type of centre, n (%) <0.001
  Academic hospital 3516 (6.4%) 2057 (20%) 1459 (3.2%)
  General hospital 42 705 (79%) 5993 (58%) 37 712 (84%)
  Private clinic 8123 (15%) 2327 (22%) 5796 (13%)
Year of colonoscopy, n (%)
  2014 616 (1.1%) 616 (5.9%)* Not applicable*
  2015 13 107 (24%) 2687 (26%) 10 420 (23%)
  2016 15 216 (27.5%) 2921 (28%) 12 295 (27%)
  2017 16 437 (30%) 2700 (26%) 13 737 (30.5%)
  2018 9968 (18%) 1453 (14%) 8515 (19%) <0.001
Quality parameters, n (%)
  Caecal intubation, n (%) 53 844 (97%) 10 061 (97%) 43 783 (97%) 0.02
  Inspection time, median (IQR) 14 (10–21) 17 (12–26) 13 (9–20) <0.001
  Inspection time ≥6 min 53 973 (97.5%) 10 276 (99%) 43 697 (97%) <0.001
  BBPS ≥2 in all segments 52 896 (96%) 9818 (95%) 43 078 (96%) <0.001
Percentages ≥10% are rounded to the nearest integer.
*Pretraining refers to baseline colonoscopies performed in 2014 prior to the first training session (trained endoscopists), or all colonoscopies in 2014 (untrained endoscopists). 
Post- training refers to all colonoscopies after the first training (trained endoscopists), or all colonoscopies from 2015 onwards (untrained endoscopists).
BBPS, Boston Bowel Preparation Score.
(≤6%), average PSPDR (6%–12%) and above- average PSPDR 
(≥12%) (figures 2 and 3).
Endoscopists with below-average PSPDR at baseline (n=5)
All five endoscopists with below- average PSPDR at baseline 
improved after the first training session. After the second 
training session, one endoscopist showed additional improve-
ment and fell in the range of above- average, while one fell back 
to the below- average range after training session 2. The other 
three remained in the range of average PSPDR after training 
session 2.
Endoscopists with average PSPDR at baseline (n=7)
Of the seven endoscopists with average PSPDR at baseline, 
four improved to above- average PSPDR after training session 
1. The second training session resulted in improvement of the 
remaining three, who also moved to above average PSPDR. In 
other words, all endoscopists with average baseline PSPDR had 
above- average PSPDR after the second training session.
Endoscopists with above-average PSPDR at baseline (n=5)
Of the five endoscopists with an above- average PSPDR at base-
line, four remained in the above- average range after training 
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Table 2 Baseline detection rates based on 928 colonoscopies 
by trained endoscopists and 6069 colonoscopies by untrained 
endoscopists*
endoscopists in 
intervention arm 
(n=17)
endoscopists in 
control arm (n=100) P value†
≥1 Proximal SP 
(=PSPDR), % (95% CI)
9.3% (7.4% to 11%) 9.3% (8.6% to 10%) 0.48
  ≥1 SP 23% (20% to 26%) 24% (23% to 25%) 0.87
  ≥1 HP 20% (17% to 22%) 20% (19% to 21%) 0.61
  ≥1 SSL 5.9% (4.4% to 7.4%) 5.4% (4.9% to 6.0%) 0.72
  ≥1 TSA 1.1% (0.4% to 1.7%) 1.4% (1.1% to 1.8%) 0.49
≥1 Adenoma (=ADR), 
% (95% CI)
66% (63% to 70%) 66% (65% to 68%) 0.99
  ≥1 Advanced 
adenoma
41% (38% to 44%) 45% (44% to 47%) 0.13
Percentages ≥10% are rounded to the nearest integer.
*Based on colonoscopies in 2014 prior to the first training session (trained 
endoscopists), or all colonoscopies in 2014 (untrained endoscopists).
†P values are based on mixed- effects logistic regression analyses, with fixed effects 
for training and adjusted with random intercepts for type of centre and endoscopist.
ADR, adenoma detection rate; HP, hyperplastic polyp; PSPDR, proximal serrated 
polyp detection rate; SP, serrated polyp; SSL, sessile serrated lesion; TSA, traditional 
serrated adenoma.
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Figure 1 (A) PSPDR before and after training; (B) ADR before and 
after training. ADR, adenoma detection rate; PSPDR, proximal serrated 
polyp detection rate.
session 1, while one fell back to average PSPDR. After training 
session 2, one additional endoscopists fell back to average 
PSPDR. In other words, three of the five endoscopists with 
above- average PSPDR at baseline also had above- average PSPDR 
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Figure 2 Effect of training sessions 1 and 2 per endoscopist, stratified 
according to their PSPDR at baseline, after the first training and after 
the second training. For example, of the seven endoscopists with 
average PSPDR at baseline, four (57%) moved up to ‘above- average 
PSPDR’ after training session 1, while three remained in the ‘average 
PSPDR’ group. PSPDR, proximal serrated polyp detection rate.
Figure 3 PSPDR before and after training. PSPDR, proximal serrated 
polyp detection rate.
after the second training session, while two fell back to average 
PSPDR.
secondary outcome measure: ADr before and after training
The ADR of trained and untrained endoscopists did not differ 
at baseline (66.5% vs 66.4%, respectively). Overall, trained 
endoscopist had an average post- training ADR of 68.5%, while 
untrained endoscopists had an average ADR of 64.1%, corre-
sponding to a relative difference of 6.9%, and an OR of 1.2 
(95% CI 1.04 to 1.38, p=0.012) for the detection of one or more 
adenomas (table 3 and figure 1B). During follow- up, the ADR 
of both trained and untrained endoscopists initially increased 
before decreasing in 2017 and 2018 to below baseline detec-
tion rates: the ADR of trained endoscopists slightly increased 
to 69.8% and 71.0% in 2015 and 2016, and then dropped to 
68.5% and 63.3% in 2017 and 2018, respectively. Comparably, 
the ADR of untrained endoscopists slightly increased to 68.8% 
in 2015, before falling to 66.7%, 62.7% and 57.1% in 2016, 
2017 and 2018, respectively (table 3 and figure 1B).
DIsCussIOn
In this large prospective trial, we demonstrate that a simple 
educational intervention was associated with substantial and 
sustained increase in PSPDR during colonoscopy within a 
homogeneous FIT- positive screening population. Considering 
that these lesions are held responsible for a disproportion-
ately high number of interval carcinomas,8 16 30 31 our inter-
vention might ultimately lead to a significant reduction in 
PCCRCs within FIT- based screening programmes. In addition, 
we demonstrate that the most prominent effect was achieved 
in endoscopists that had a below- average PSPDR at base-
line (figure 2), suggesting this intervention should be mainly 
targeted at the low- performers.
Interpreting our findings, lack of awareness about SPs might 
be one of the most important contributors to the highly vari-
able (and often suboptimal) SP detection as described in previous 
studies.11 12 After all, the content of our training sessions mostly 
focused on why SPs should be detected and resected, rather 
than how this should be done. This might be due to the fact 
that the contribution of SPs to CRC has only gradually come 
into focus over the past two decades.5 9 32–35 Many endoscopists 
were trained in an era in which adenomas were considered the 
sole precursors to CRC, or were trained by endoscopists that 
were trained in this pre- SP era. Indeed, a recent large multi-
centre study by Crockett et al demonstrated that endoscopists 
with fewer years of practice detected significantly more SPs than 
their older colleagues.36
Apart from the increased SP detection, we saw an interesting 
time- trend in the ADR: after initially increasing, both groups 
showed a decreasing ADR in 2017 and 2018 (figure 1B). This 
trend was in line with an overall slow decrease in ADR in our 
national screening programme. This can be attributed to three 
factors related to the implementation of the Dutch biennial FIT- 
based screening programme from 2014 onwards: an increase of 
the iFOBT cut- off from 88 to 275 ng/mL in 2014. First, the 
initial increase in ADR was most likely a result of the increase 
of the cut- off of the iFOBT from 88 to 275 ng/mL.37 The subse-
quent decrease in ADR can be attributed to the decreasing age 
of invitees from 2015 onwards, which was in turn a result of 
the phased invitation of screenees from 2014 to 2019 (online 
supplementary figure 1). Lastly, the screening programme 
consists of biennial FIT. As a result, the proportion of partici-
pants in their second- round or third test- round grew from 0% 
in 2014 and 2015, to 30% in 2016 and 53% in 2017.37–40 In 
line with literature,41–44 the second- round/third- round screenees 
had a lower incidence of CRC, advanced adenomas and non- 
advanced adenomas, which reflects the lower positive predictive 
value of FIT after multiple test- rounds. Regardless of this overall 
trend, endoscopists that received our SP detection training 
seemed to have a slightly higher ADR than endoscopists that did 
not receive our training (p=0.012). Although statistically signif-
icant, the clinical relevance of this minor difference in ADR is 
questionable. The reason for this difference in ADR between 
intervention and control group is unclear, but could potentially 
relate to the longer withdrawal time in the intervention group. 
Alternatively, more thorough mucosal inspection in search of 
SPs in the intervention group might have also resulted in higher 
detection of adenomas.
To interpret our results, it should be questioned whether 
these background developments in the population screening 
programme might have also affected our study outcomes. This 
does not seem to be the case because these developments have 
equally affected the intervention and control arm of our study.
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Our study has several strengths. First of all, this is the first study 
focusing on educational interventions to improve SP detection. 
Such targeted interventions are needed, as Racho et al showed 
that training focused on improving ADR detection had no effect 
whatsoever on SP detection, despite its long- lasting beneficial 
effect on ADR.22 Second, we had the opportunity to perform 
our study within the Dutch FIT- based screening programme. 
This allowed us to include a large number of endoscopists and 
colonoscopies. Our cohort of 17 intervention and 100 control 
endoscopists can be considered large compared with the well- 
known EQUIP trial which assessed the effectivity of a training 
which aimed to improve ADR, in which eight and seven endos-
copists were randomised into the intervention and control arm, 
respectively.19 Equally important, nesting our study in the Dutch 
screening programme provided us with a prospectively collected 
database of a homogeneous group of patients with high- quality 
colonoscopies performed by accredited endoscopists. Quality 
indicators (ie, bowel preparation, caecum intubation and inspec-
tion time) were each met in over 95% of colonoscopies (table 1). 
Third, we included almost 5 years of prospective follow- up data, 
which allowed us to assess the long- term impact of our educa-
tional intervention. Last, the histopathological assessment, espe-
cially the SP subclassification, can be considered high quality as 
well since all pathologists received online training in order to 
optimise correct SP diagnosis. This online training module was 
shown to be very effective.45
Nevertheless, several alternative explanations for the 
improved PSPDR have to be considered as well. First of all, 
trained endoscopists were aware of the fact that they partici-
pated in this study, while the untrained endoscopists were not. 
As such, the Hawthorne effect, which describes an individual’s 
change in behaviour due to awareness of being observed,46 might 
have positively influenced the PSPDR of trained, but not of 
untrained endoscopists. However, we believe this effect has not 
played a major role in our study. First, the awareness of being 
monitored among trained endoscopists was kept to an absolute 
minimum in order to minimise interference of the Hawthorne 
effect. The background monitoring of PSPDR was only commu-
nicated verbally during both training sessions. Aside from these 
brief occasions in 2014 and 2017, no communication existed 
between the researchers and the endoscopists, and the endos-
copists were not reminded in any other way about our ongoing 
study. It therefore seems likely that our ongoing study was not on 
top of the mind of participating endoscopists during their daily 
work in the 5 years of follow- up. Moreover, all Dutch endos-
copists are aware that they are being monitored as part of stan-
dard care, since they continuously have to meet several minimal 
quality requirements (eg, ADR ≥30%).25 Since endoscopists 
face penalties when they fail to reach such quality parameters 
(eg, withdrawal of accreditation), our monitoring was probably 
perceived as far less urgent and thus received less attention from 
endoscopists than the ongoing quality assurance parameters they 
were confronted with in daily practice. Nevertheless, it seems 
advisable that future similar studies make the control arm aware 
of the fact that they are monitored too, in order to reduce any 
potential influence of the Hawthorne effect.
Furthermore, our study was not randomised, and therefore 
we cannot rule out some degree of selection bias. Baseline differ-
ences between the trained and untrained endoscopists might 
have played a role in the increased detection rates we observed 
in the trained group. First of all, trained endoscopists more 
often operated in academic centres (12% vs 24%, p<0.001). 
However, we accounted for this by including type of centre in 
our multivariable model. In addition, our regression analyses did 
not show any association between type of centre and PSPDR, 
neither in trained or untrained endoscopists. Moreover, we ran 
separate sensitivity analyses in which we excluded colonosco-
pies in academic centres, which yielded similar results. A second 
baseline difference concerns the mucosal inspection time (16 vs 
13 min, p<0.001), suggesting trained endoscopists already took 
slightly more time for mucosal inspection than untrained endos-
copists before their first training. However, although a prolonged 
withdrawal time has been linked to superior ADR,47–51 both 
groups exceeded withdrawal times of 10 min. A study by Lee et 
al demonstrated that the additional benefit of withdrawal times 
beyond 10 min is questionable, and minimal at best.51 We there-
fore consider it unlikely that this baseline difference represents a 
clinically relevant bias.
We cannot rule out that these or other baseline differences 
might have influenced our results. Most importantly, however, 
our baseline comparison of detection rates shows that across all 
polyp subtypes, detection rates of trained and untrained endos-
copists were virtually identical (table 2). This strongly suggests 
that trained and untrained endoscopists were indeed ‘equal’ at 
baseline.
Several other limitations have to be acknowledged as well. 
We chose to include endoscopists that attended both training 
sessions only, which meant several had to be excluded due to 
absence during either training session. Since attendance was 
voluntary, this might have led to selection of more devoted 
or motivated endoscopists. Considering that the effect of our 
training strongly relies on endoscopists’ motivation to pay extra 
attention to serrated lesions, this selection might have caused 
an overestimation of our outcome parameters. However, this 
potential selection bias seems less plausible taking into account 
our sensitivity analysis, in which endoscopists that only partici-
pated in one of the two training sessions also showed an increase 
in PSPDR from 10.6% to 12.8%, although this was not signifi-
cantly different from the untrained group (p=0.13), possibly 
due to the small subgroup sample size (3464 colonoscopies in 
11 endoscopists).
Another limitation was the scarcity of endoscopist character-
istics we could include in our analysis. It would have been very 
informative to assess whether characteristics like age, years of 
experience or gender might predict the effect of our interven-
tion. Unfortunately, such parameters could not be provided by 
the RIVM because their database did not contain this informa-
tion. Finally, our secondary analyses to assess which endoscopists 
benefited most from our interventions required us to split up our 
intervention group in three subgroups. The resulting subgroups 
are quite small (ie, five, seven and five endoscopists in the below- 
average, average and above- average groups, respectively). These 
subgroup analyses should therefore be interpreted with caution 
and warrant validation in future larger studies.
Our results would ideally be interpreted in the light of estab-
lished, evidence- based targets for PSPDR to optimise PCCRC 
prevention, similar to the studies that were used to guide ADR 
targets. For example, Kaminski et al demonstrated that an 
ADR of at least 20% was associated with a much lower risk of 
PCCRC,17 while Corley et al later demonstrated that every 1% 
increase in ADR was associated with a 3% decrease in PCCRC 
incidence.18 Such data have been invaluable in determining clin-
ically meaningful ADR targets. Unfortunately, no such data have 
been published on SP detection rates, and therefore it is much 
more difficult to determine clinically meaningful PSPDR targets 
at this moment. We do know, however, that PCCRCs dispropor-
tionately often bear typical molecular and clinical characteristics 
of the serrated pathway, and therefore it is generally believed 
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that missing SPs is an important factor in PCCRC develop-
ment.5 8 16 52 This suggests that improvement of SP detection 
would result in a decline in PCCRC incidence. Indeed, recently 
the British Society for Gastroenterology even suggested that 
improvement of SP detection might have a greater impact on 
PCCRC incidence than improvement of ADR.8 In this light, and 
in the absence of established thresholds, it seems safe to assume 
that any improvement in PSPDR might be clinically relevant. 
Future studies will hopefully help to establish evidence- based 
PSPDR thresholds to further guide the implementation and 
targeting of quality improvement interventions such as ours.
In conclusion, our results show that improvement of SP detec-
tion can be achieved relatively easily by a simple educational 
intervention, which consists of two 45 min training sessions 
which are held 3 years apart. Giving SPs a more prominent 
place in current endoscopy programme could potentially lead to 
improved CRC prevention. Endoscopists with a low PSPDR at 
baseline benefited most from our intervention, which supports 
introduction of continuous PSPDR monitoring in order to iden-
tify and target low performers and provide additional training 
to them.
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